Taigen Biopharmaceuticals Holdings Ltd (4157) — Long-term Investment Intensity
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Long-term Investment Intensity of 14.1% as of December 2019. Long-term investments of NT$133.82 Million represent 14.1% of total assets of NT$946.11 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See shareholders equity of Taigen Biopharmaceuticals Holdings Ltd for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Taigen Biopharmaceuticals Holdings Ltd Long-term Investment Intensity (2017–2019)
This chart shows how Taigen Biopharmaceuticals Holdings Ltd's Long-term Investment Intensity has evolved across 3 annual periods from 2017 to 2019. As of December 2019, the intensity stands at 14.1%, reflecting long-term investments of NT$133.82 Million against total assets of NT$946.11 Million TWD. Also explore 4157 total assets for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for Taigen Biopharmaceuticals Holdings Ltd (2017–2019)
The table below presents the year-by-year Long-term Investment Intensity for Taigen Biopharmaceuticals Holdings Ltd from 2017 to 2019, covering 3 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see market value of Taigen Biopharmaceuticals Holdings Ltd.
| Year | LT Investment Intensity | LT Investments (TWD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 14.1% | NT$133.82 Million | NT$946.11 Million | ▼ -9.4 pp |
| 2018 | 23.6% | NT$280.07 Million | NT$1.19 Billion | ▼ -1.2 pp |
| 2017 | 24.8% | NT$376.91 Million | NT$1.52 Billion | — |